BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/24/2022 9:00:24 AM | Browse: 289 | Download: 529
 |
Received |
|
2021-11-23 06:52 |
|
Peer-Review Started |
|
2021-11-23 06:54 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-04-08 00:11 |
|
Revised |
|
2022-04-16 12:18 |
|
Second Decision |
|
2022-05-07 07:56 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-05-08 07:04 |
|
Articles in Press |
|
2022-05-08 07:04 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-04-29 03:27 |
|
Typeset the Manuscript |
|
2022-05-23 01:19 |
|
Publish the Manuscript Online |
|
2022-06-24 09:00 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Urology & Nephrology |
| Manuscript Type |
Case Report |
| Article Title |
Roxadustat for treatment of anemia in a cancer patient with end-stage renal disease: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Qiao-Qiao Zhou, Jing Li, Bin Liu and Chun-Li Wang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jing Li, PhD, Professor, Hemodialysis Room, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No. 55 Section 4, Renmin South Road, Chengdu 610042, Sichuan Province, China. 24978201@qq.com |
| Key Words |
Cancer; End-stage renal disease; Hemodialysis; Anemia; Roxadustat; Case report |
| Core Tip |
Currently, erythropoiesis-stimulating agents (ESAs) are the cornerstones for the treatment of renal anemia or cancer-related anemia. Roxadustat is a newly developed drug for renal anemia treatment, but not for cancer-related anemia, let alone to treat anemia in cancer patients with end-stage renal disease (ESRD). At the beginning, the patient was treated with high-dose ESAs, iron supplementation, and even blood transfusion, but his anemia did not improve. However, after orally taking roxadustat, his hemoglobin gradually increased without significant tumor progression. This is the first case using roxadustat to successfully improve anemia in a cancer patient with ESRD. |
| Publish Date |
2022-06-24 09:00 |
| Citation |
Zhou QQ, Li J, Liu B, Wang CL. Roxadustat for treatment of anemia in a cancer patient with end-stage renal disease: A case report. World J Clin Cases 2022; 10(19): 6587-6594 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i19/6587.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i19.6587 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
